Results 41 to 50 of about 169,475 (267)

The ubiquitin‐proteasome system and autophagy as guardians of the cellular proteome

open access: yesFEBS Letters, EarlyView.
This Perspective covers the three principles governing the crosstalk between the ubiquitin‐proteasome system and autophagy in cellular proteostasis: (1) a shared ubiquitin code routing substrates via shuttle factors or autophagy receptors; (2) spatial compartmentalization into phase‐separated degradation hubs and organelle‐specific modules (exemplified
Ivan Dikic
wiley   +1 more source

Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction

open access: yesScientific Reports, 2017
JAK2 activation is crucial for cytokine receptor signal transduction and leukemogenesis. However, the underlying processes that lead to full activation of JAK2 are unclear.
Chun-Shan Liu   +4 more
doaj   +1 more source

Regulation of Glucose, Fatty Acid and Amino Acid Metabolism by Ubiquitination and SUMOylation for Cancer Progression

open access: yesFrontiers in Cell and Developmental Biology, 2022
Ubiquitination and SUMOylation, which are posttranslational modifications, play prominent roles in regulating both protein expression and function in cells, as well as various cellular signal transduction pathways. Metabolic reprogramming often occurs in
Shunqin Zhu   +9 more
doaj   +1 more source

Ubiquitination of secretory granules promotes their crinophagic degradation in Drosophila

open access: yesFEBS Letters, EarlyView.
Ubiquitination of secretory granules in Drosophila larval salivary glands is a critical molecular trigger for crinophagy, the lysosomal degradation of unreleased, or low‐quality granules. The E3 ubiquitin ligase Cnot4 is recruited to the surface of secretory granules to induce crinophagy.
Tamás Csizmadia   +6 more
wiley   +1 more source

Engineering ubiquitin to modulate the ubiquitin proteosome system [PDF]

open access: yesCell Cycle, 2013
(2013). Engineering ubiquitin to modulate the ubiquitin proteosome system. Cell Cycle: Vol. 12, No. 11, pp. 1651-1652.
Andreas, Ernst, Sachdev S, Sidhu
openaire   +2 more sources

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

open access: yesMolecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain   +10 more
wiley   +1 more source

The ubiquitin code of RAS proteins: Decoding its role in cancer progression

open access: yesiScience
Summary: RAS proteins, as the most frequently mutated oncoproteins in human cancers, drive tumor proliferation, metastasis, and therapeutic resistance.
Yedan Shi   +6 more
doaj   +1 more source

Elevated ubiquitination contributes to protective immunity against severe SARS‐CoV‐2 infection

open access: yesClinical and Translational Medicine, 2022
Background The crosstalk between the ubiquitin‐proteasome and the immune system plays an important role in the health and pathogenesis of viral infection.
Yinggang Che   +16 more
doaj   +1 more source

The roles of protein ubiquitination in tumorigenesis and targeted drug discovery in lung cancer

open access: yesFrontiers in Endocrinology, 2023
The malignant lung cancer has a high morbidity rate and very poor 5-year survival rate. About 80% - 90% of protein degradation in human cells is occurred through the ubiquitination enzyme pathway.
Zhen Ye   +4 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy